Abstract
Background
Minimal residual disease (MRD) and hematopoietic chimerism testing influences clinical decision and therapeutic intervention in patients after allogeneic stem cell transplantation (HSCT). However, treatment approaches to induce complete donor chimerism and MRD negativity can lead to complications such as graft-versus-host disease (GvHD) and marrow aplasia. Therefore, there is a need for comprehensive characterization of the molecular remission status after transplantation.
Methods
We analyzed 764 samples from 70 patients after HSCT for the simultaneous measurement of chimerism and molecular targets used for MRD testing with a digital PCR (dPCR) platform.
Results
Mixed chimerism (MC) was detected in 219 samples from 37 patients. The mean percentage of host derived DNA in these clinical samples was 4.3%. Molecular relapse with a positive MRD marker and/or increased WT1 expression was observed in 15 patients. In addition to WT1 overexpression, other MRD positive markers were: NPM1 (Type A, B, K), DNMT3A (R882H), MLL-PTD, IDH1 (R132H) and KRAS (G12S). Increasing MC was observed in 15 patients. This group of patients showed either a positive MRD marker, increased WT1 expression or both. Next, we analyzed whether MC or the molecular target for MRD was first detected. MC and MRD marker positivity in this group was first detected in six and two patients, respectively. In the remaining seven patients MC and MRD positivity was detected simultaneously.
Conclusions
The combination of MRD and chimerism markers in a dPCR platform represents a practical, sensitive and accurate diagnostic tool for the comprehensive assessment of the molecular remission status of patients undergoing HSCT.
Acknowledgments
The authors thank Sabine Enger, Sabine Lilli, Ingrid Huber, Marlene Asch, Andreas Janes and Edith März for technical assistance.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Jacobsohn DA, Loken MR, Fei M, Adams A, Brodersen LE, Logan BR, et al. Outcomes of measurable residual disease in pediatric acute myeloid leukemia pre- and post-hematopoietic stem cell transplant: validation of difference from normal flow cytometry with chimerism studies and Wilms tumor 1 gene expression. Biol Blood Marrow Transplant 2018 Jun 19. pii: S1083-8791(18)30322-7. doi: 10.1016/j.bbmt.2018.06.010. [Epub ahead of print].10.1016/j.bbmt.2018.06.010Search in Google Scholar PubMed PubMed Central
2. Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y, et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol 2016;34:329–36.10.1200/JCO.2015.63.3826Search in Google Scholar PubMed PubMed Central
3. Choi SJ, Lee KH, Lee JH, Kim S, Chung HJ, Lee JS, et al. Pronogstic value of hematopoietic chimerism in patients with acute leukemia after allogeneic bone marrow transplantation: a prospective study. Bone Marrow Transplant 2000;26:327–32.10.1038/sj.bmt.1702504Search in Google Scholar PubMed
4. Kreyenberg H, Hölle W, Möhrle S, Niethammer D, Bader P. Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: the Tuebingen experience. Leukemia 2003;17:237–40.10.1038/sj.leu.2402761Search in Google Scholar PubMed
5. Alizadeh M, Bernard M, Danic B, Dauriac C, Birebent B, Lapart C, et al. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood 2002;99:4618–25.10.1182/blood.V99.12.4618Search in Google Scholar
6. Waterhouse M, Pfeifer D, Follo M, Duyster J, Schäfer H, Bertz H, et al. Early mixed hematopoietic chimerism detection by digital droplet PCR in patients undergoing gender-mismatched hematopoietic stem cell transplantation. Clin Chem Lab Med 2017;55:1115–21.10.1515/cclm-2016-0900Search in Google Scholar PubMed
7. Aloisio M, Licastro D, Caenazzo L, Torboli V, D’Eustacchio A, Severini GM, et al. A technical application of quantitative next generation sequencing for chimerism evaluation. Mol Med Rep 2016;14:2967–74.10.3892/mmr.2016.5593Search in Google Scholar PubMed PubMed Central
8. Lee HC, Saliba RM, Rondon G, Chen J, Charafeddine Y, Medeiros LJ, et al. Mixed T lymphocyte chimerism after allogeneic hematopoietic transplantation is predictive for relapse of acute myeloid leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant 2015;21:1948–54.10.1016/j.bbmt.2015.07.005Search in Google Scholar PubMed PubMed Central
9. Terwey TH, Hemmati PG, Nagy M, Pfeifer H, Gökbuget N, Brüggemann M, et al. Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2014;20:1522–9.10.1016/j.bbmt.2014.05.026Search in Google Scholar PubMed
10. Zeiser R, Spyridonidis A, Wäsch R, Ihorst G, Grüllich C, Bertz H, et al. Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation. Leukemia 2005;19:814–21.10.1038/sj.leu.2403719Search in Google Scholar PubMed
11. Stahl T, Böhme MU, Kröger N, Fehse B. Digital PCR to assess hematopoietic chimerism after allogeneic stem cell transplantation. Exp Hematol 2015;43:462–8.10.1016/j.exphem.2015.02.006Search in Google Scholar PubMed
12. George D, Czech J, John B, Yu M, Jennings LJ. Detection and quantification of chimerism by droplet digital PCR. Chimerism 2013;4:102–8.10.4161/chim.25400Search in Google Scholar PubMed PubMed Central
13. Sellmann L, Rabe K, Bünting I, Dammann E, Göhring G, Ganser A, et al. Diagnostic value of highly-sensitive chimerism analysis after allogeneic stem cell transplantation. Bone Marrow Transplant 2018 May 2. doi: 10.1038/s41409-018-0176-7. [Epub ahead of print].10.1038/s41409-018-0176-7Search in Google Scholar PubMed
14. Marks R, Potthoff K, Hahn J, Ihorst G, Bertz H, Spyridonidis A, et al. Reduced-toxicity conditioning with fludarabine, BCNU and melphalan in allogeneic cell transplantation: particular activity against advanced hematologic malignancies. Blood 2008;112:415–25.10.1182/blood-2007-08-104745Search in Google Scholar PubMed
15. Clark JR, Scott SD, Jack AL, Lee H, Mason J, Carter GI, et al. Monitoring of chimerism following allogeneic haematopoietic stem cell transplantation (HSCT): technical recommendations for the use of short tandem repeats (STR) based techniques, on behalf of the United Kingdom National External Quality Assessment service for Leucocyte Immunophenotyping Chimerism Working Group. Br J Haematol 2015;168:26–37.10.1111/bjh.13073Search in Google Scholar PubMed
16. Clinical and Laboratory Standards Institute. EP17-A2 Evaluation of detection capability for Clinical Laboratory Measurement Procedures; Approved Guideline-Second Edition. Wayne, PA: CLSI;2013.Search in Google Scholar
17. Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, Jovanovic JV, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 2009;27:5195–201.10.1200/JCO.2009.22.4865Search in Google Scholar PubMed
18. Frey NV, Porter DL. Graft-versus-host disease after donor leukocyte infusions: presentation and management. Best Pract Res Clin Haematol 2008;38:399–405.10.1016/j.beha.2008.02.007Search in Google Scholar PubMed PubMed Central
19. Garicochea B, van Rhee F, Spencer A, Chase A, Lin F, Cross NC, et al. Aplasia after donor lymphocyte infusion (DLI) for CML in relapse after sex-mismatched BMT: recovery of donor-type haemopoiesis predicted by non-isotopic in situ hybridization (ISH). Br J Haematol 1994;88:400–2.10.1111/j.1365-2141.1994.tb05039.xSearch in Google Scholar PubMed
20. Waterhouse M, Follo M, Pfeifer D, von Bubnoff N, Duyster J, Bertz H, et al. Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR. Ann Hematol 2016;95:739–44.10.1007/s00277-016-2623-0Search in Google Scholar PubMed
21. Ommen HB, Hokland P, Haferlach T, Abildgaard L, Alpermann T, Haferlach C, et al. Relapse kinetics in acute myeloid leukemias with MLL translocations or partial tandem duplications within the MLL gene. Br J Haematol 2014;165:618–28.10.1111/bjh.12792Search in Google Scholar PubMed
22. Papadaki C, Dufour A, Seibl M, Schneider S, Bohlander SK, Zellmeier E, et al. Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor. Br J Haematol 2009;144:517–23.10.1111/j.1365-2141.2008.07488.xSearch in Google Scholar PubMed
©2019 Walter de Gruyter GmbH, Berlin/Boston
